BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2025 8:16:42 AM | Browse: 113 | Download: 291
 |
Received |
|
2025-05-19 01:58 |
|
Peer-Review Started |
|
2025-05-19 01:58 |
|
First Decision by Editorial Office Director |
|
2025-06-05 09:38 |
|
Return for Revision |
|
2025-06-05 09:38 |
|
Revised |
|
2025-06-14 09:36 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-08-04 02:52 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-08-04 11:41 |
|
Articles in Press |
|
2025-08-04 11:41 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-08-18 00:17 |
|
Publish the Manuscript Online |
|
2025-08-21 08:16 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Affan Faisal, Abdul Basit, Abdullah Iftikhar, Muneeb Saifullah, M Khalil ur Rehmaan and Abdul M Basil |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abdul M Basil, MD, Department of Medicine, Spinghar Medical University, 4th Alley, Char Rahe Qambar Kabul, Kabul 1001, Afghanistan. abdulmaboodbasil@outlook.com |
| Key Words |
Lepodisiran; Gene targeting; Atherosclerotic cardiovascular disease; Lipid lowering agents; Cardiovascular medicine |
| Core Tip |
Lepodisiran is a novel N-acetylgalactosamine-conjugated small interfering RNA that durably reduces lipoprotein(a) [Lp(a)] levels by silencing hepatic LPA message RNA expression. It offers up to 94% sustained Lp(a) reduction with minimal side effects and extended dosing intervals (6-12 months). This therapeutic breakthrough addresses a key residual cardiovascular risk factor previously untreatable with conventional lipid-lowering agents. |
| Publish Date |
2025-08-21 08:16 |
| Citation |
Faisal A, Basit A, Iftikhar A, Saifullah M, Rehmaan MKU, Basil AM. Lepodisiran: From genetic targeting to cardiovascular promise: A detailed narrative review of the literature. World J Cardiol 2025; 17(8): 109657 |
| URL |
https://www.wjgnet.com/1949-8462/full/v17/i8/109657.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v17.i8.109657 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
